Bristol-Myers Squibb Company (BMY) Guidance & Earnings Results

On 2026-07-30 Bristol-Myers Squibb Company raised guidance: "FY26 revenue raised to ~$49.0-50.0B from ~$46.0-47.5B; FY26 non-GAAP EPS raised to $6.75-7.00 from $6.05-6.35; FY26 Eliquis revenue growth raised to 20-25% from 10-15%; FY26 operating expenses ~$16.5B (from ~$16.3B);…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BMYBristol-Myers Squibb CompanyFollow BMY — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 125.6B
P/E TTM: 13.5
Dividend yield: 4.1%
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	FY26 revenue raised to ~$49.0-50.0B from ~$46.0-47.5B; FY26 non-GAAP EPS raised to $6.75-7.00 from $6.05-6.35; FY26 Eliquis revenue growth raised to 20-25% from 10-15%; FY26 operating expenses ~$16.5B (from ~$16.3B); Gross margin ~69-70% (unchanged); Effective tax rate ~18% (unchanged) · full year
30 Apr 26	Reaffirmed	Revenue guidance ~$46.0B-$47.5B; non-GAAP EPS $6.05-$6.35, trending toward upper end · full year
5 Feb 26	Lowered	FY2026 revenue $46.0-$47.5B (down from $48.2B FY2025); non-GAAP EPS $6.05-$6.35 (down from $6.15 FY2025 midpoint) · full year
30 Oct 25	Raised	Revenue guidance raised to ~$47.5-48.0B; non-GAAP EPS $6.40-6.60 · full year
31 Jul 25	Raised	FY2025 revenue raised to ~$46.5-47.5B (from prior ~$46B?); non-GAAP EPS updated to $6.35-6.65 including $(0.57) BioNTech IPRD charge (prior $6.60-6.90?); Q2 non-GAAP EPS $1.46. · full year

Bristol-Myers Squibb Company — questions

What guidance did Bristol-Myers Squibb Company give?: On 2026-07-30: "FY26 revenue raised to ~$49.0-50.0B from ~$46.0-47.5B; FY26 non-GAAP EPS raised to $6.75-7.00 from $6.05-6.35; FY26 Eliquis revenue growth raised to 20-25% from 10-15%; FY26 operating expenses ~$16.5B (from ~$16.3B); Gross margin ~69-70% (unchanged); Effective tax rate ~18% (unchanged)"
When does Bristol-Myers Squibb Company report earnings?: Bristol-Myers Squibb Company's next earnings report is expected on 2026-10-29.

Every figure on this page comes from Bristol-Myers Squibb Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.